Allogeneic BMT for acute lymphoblastic leukemia in adults - long term survival

From October 1984 to March 199, 64 patients with acute lymphoblastic leukemia in first or second complete remission received allogeneic bone marrow from therir HLA-identical sibling. Median age was 28 (range 18-49 years). Patients were conditioned with cyclophosphamide 120 mg/kg and total body irradiation (TBI), 12 Gy, at a dose rate of 2.9-5.7 cGy/min in a three 4Gy fractions given daily over 3 days. For GVHD prophylaxis patients received cyclosporine alone or standard short methotrexate and cyclosporine. Amedian of 2.1 (range 1.2-5.2) x 10E8/kg of marrow cells were infused. The median follow-up period is 85 months (range 6-150). Overall probability of LFS is 35% at 60 months. Patients allografted in first CR had better LFS 52% compared to the patients treated in second CR, 30% (p